Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Medtronic
Moodys
Harvard Business School
McKesson
Dow

Last Updated: December 1, 2021

DrugPatentWatch Database Preview

Investigational Drug Information for Abrocitinib


Email this page to a colleague

« Back to Dashboard

What is the drug development status for Abrocitinib?

Abrocitinib is an investigational drug.

There have been 8 clinical trials for Abrocitinib. The most recent clinical trial was a Phase 3 trial, which was initiated on June 11th 2018.

The most common disease conditions in clinical trials are Dermatitis, Atopic, Dermatitis, and Eczema. The leading clinical trial sponsors are Pfizer, Duke University, and Johns Hopkins University.

There are five US patents protecting this investigational drug and ninety-five international patents.

Recent Clinical Trials for Abrocitinib
TitleSponsorPhase
JAK Inhibition in Food AllergyIcahn School of Medicine at Mount SinaiPhase 1
A Study to Estimate the Effect of Multiple Dose Abrocitinib on Caffeine, Efavirenz, and Omeprazole in Healthy ParticipantsPfizerPhase 1
Efficacy of Abrocitinib for Reducing Pruritus in Adults With Prurigo Nodularis and Chronic Pruritus of Unknown OriginDuke UniversityPhase 2

See all Abrocitinib clinical trials

Clinical Trial Summary for Abrocitinib

Top disease conditions for Abrocitinib
Top clinical trial sponsors for Abrocitinib

See all Abrocitinib clinical trials

US Patents for Abrocitinib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Abrocitinib ⤷  Try it Free Aza-indazole compounds for use in tendon and/or ligament injuries NOVARTIS AG (Basel, CH) ⤷  Try it Free
Abrocitinib ⤷  Try it Free Manufacturing process and intermediates for a pyrrolo[2,3-d]pyrimidine compound and use thereof Pfizer Inc. (New York, NY) ⤷  Try it Free
Abrocitinib ⤷  Try it Free Pyrrolo[2,3-D]pyrimidine derivatives Pfizer Inc. (New York, NY) ⤷  Try it Free
Abrocitinib ⤷  Try it Free Pyrrolo[2,3-D]pyrimidine derivatives Pfizer Inc. (New York, NY) ⤷  Try it Free
Abrocitinib ⤷  Try it Free Pyrrolo[2,3-D]pyrimidine derivatives Pfizer Inc. (New York, NY) ⤷  Try it Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Abrocitinib

Drugname Country Document Number Estimated Expiration Related US Patent
Abrocitinib Australia AU2017332868 2036-09-23 ⤷  Try it Free
Abrocitinib Brazil BR112019005318 2036-09-23 ⤷  Try it Free
Abrocitinib Canada CA3033253 2036-09-23 ⤷  Try it Free
Abrocitinib Chile CL2019000768 2036-09-23 ⤷  Try it Free
Abrocitinib China CN109715629 2036-09-23 ⤷  Try it Free
Abrocitinib Colombia CO2019002618 2036-09-23 ⤷  Try it Free
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Medtronic
Moodys
Harvard Business School
McKesson
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.